| Purpose:In this study,we observed the changes of clinical symptoms,serum sex hormones Estradiol(Estradiol,E2)、follicular stimulating hormone(follicular stimulating hormone,FSH)、luteinzing hormone(luteinzing hormone,LH)and Anti-Mullerian hormone(Anti-Mullerian hormone,AMH)before and after the treatment of menopausal syndrome with Yin deficiency and fire excess syndrome,and evaluated the clinical effect of new gengaian prescriptions on menopausal syndrome with Yin deficiency and fire exeess syndrome.We also observed the changes of serum interleukin-6(interleukin-6,IL-6)and T cell subsets before and after the treatment,and discussed the effect of new gengaian prescriptions on improving the body of menopausal patients The mechanism of immune function.Method:From March 2019 to March 2020,60 patients with menopausal syndrome who met the criteria of this case selection were collected from the gynecological clinic of Jiangsu Hospital of traditional Chinese medicine.They were randomly divided into treatment group and control group with 30 cases each.Treatment group:new gengaian prescriptions(decoction),oral,1 dose/day,morning and evening;control group:Kuntai Capsule,oral,4 capsules,3 times/day;a month for a course,a total of two courses of observation.The data collected were analyzed by SPSS 22.0 statistical software,and the improvement of symptoms(syndrome score and modified Kupperman score),serum sex hormone E2,FSH,LH,AMH,interleukin-6 and T cell level were compared before and after treatment in the two groups.Result:1.Improvement of clinical symptoms(1)The score of the treatment group before treatment was 25.50±5.26,after treatment was 18.40 ± 5.35,the score of the control group before treatment was 24.60 ± 4.62,and the score of the control group after treatment was 21.50 ± 5.56.The modified Kupperman score of the two groups before and after treatment was significantly reduced(P<0.01);compared between the groups,the modified Kupperman seore of the treatment group after treatment was significantly lower than that of the control group(P<0.05).(2)Syndrome score:Before and after treatment,the scores of the treatment group were 25.57 ± 4.01,7.10± 4.20,25.67 ± 2.64 and 10.87 ± 5.14,respectively,which were significantly lower than those of the control group(P<0.01);compared between the groups,the syndrome score of the treatment group was significantly lower than that of the control group(P<0.01).2.Changes of serum E2,FSH and LH levels:(1)E2 value:The E2 value of the treatment group was 24.00 ± 3.66 before treatment,30.93± 4.90 after treatment,24.67 ± 3.44 before treatment and 28.33 ± 3.97 after treatment.The E2 value of the treatment group was significantly higher than that of the control group(P<0.01);compared between the groups,the E2 value of the treatment group was significantly higher than that of the control group(P<0.05).(2)FSH value:FSH value before treatment in the treatment group was 74.86±13.83,after treatment was 65.71 ± 12.72,before treatment in the control group was 67.74 ± 14.42,after treatment was 59.95±11.60,FSH value before and after treatment in the two groups were significantly reduced(P<0.01);comparison between groups:there was no significant difference in FSH value between the two groups after treatment(P>0.05).(3)LH value:before treatment,the value of LH in the treatment group was 34.59±11.70,after treatment,29.80±10.57;before treatment,the value of LH in the control group was 37.30±13.04,after treatment,31.84±11.77,both before and after treatment,the value of LH in the two groups were significantly reduced(P<0.01);comparison between groups:after treatment,there was no significant difference between the two groups(P>0.05).3.Changes of serum AMH level:The AMH value of the treatment group was 0.10 ± 0.07 before treatment,0.11 ± 0.07 after treatment,0.12± 0.06 before treatment and 0.12± 0.05 after treatment.The AMH value of the treatment group was significantly higher than that before treatment(P<0.05).The AMH value of the control group was not significantly higher than that before treatment(P>0.05).Comparison between groups:there was no significant difference between the AMH values of the two groups after treatment(P>0.05).4.Correlation between serum AMH level and E2,FSH and LH levels before treatment:There was a significant positive correlation between AMH and E2,the difference was statistically significant(P<0.01);there was a strong negative correlation between AMH and FSH,the difference was statistically significant(P<0.01);there was no significant correlation between AMH and LH,the difference was not statistically significant(P>0.05).5.Changes of serum IL-6 level:The value of IL-6 in the treatment group was 18.04 ± 5.44 before treatment,16.11± 4.43 after treatment,19.77 ± 4.36 before treatment and 18.38± 3.79 after treatment.The value of IL-6 in the treatment group was significantly lower than that before treatment(P<0.01).The value of IL-6 in the control group was significantly lower than that before treatment(P<0.05).Compared with the control group,the value of IL-6 in the treatment group was significantly lower than that in the control group(P<0.05).6.Changes of T cell subsets:The values of CD3,CD4,CD8 and CD4/CD8 in the treatment group were 48.14 ± 4.50,26.79 ± 3.84,31.63 ± 3.54 and 0.86 ± 0.17,respectively,and the values of CD3,CD4,CD8 and CD4/CD8 after treatment were 61.68 ± 5.35,39.11± 4.40,27.25 ± 4.87 and 1.47 ± 0.21,The values of CD3,CD4,CD8 and CD4/CD8 in the control group were 50.62 ± 5.60,26.76 ± 3.06,31.03 ± 3.46 and 0.87 ± 0.13 respectively before and after treatment,and the values of CD3,CD4,CD8 and CD4/CD8 in the treatment group were 59.07±3.84,37.00 ± 4.16,28.54 ± 3.71 and 1.32± 0.24 respectively.The values of CD3,CD4 and CD4/CD8 in the two groups before and after treatment were significantly higher than those before treatment(P<0.01);the values of CD8 in the treatment group after treatment were significantly lower than those before treatment(P<0.01)After treatment,the CD8 value in the control group was significantly lower than that before treatment(P<0.05);compared between the groups,the CD3 and CD4/CD8 of the treatment group were significantly higher than those of the control group(P<0.05),and there was no significant difference between the two groups(P>0.05).7.Comprehensive clinical efficacy:In the treatment group,4 cases were cured(13%),16 cases were effective(53%),8 cases were effective(27%),2 cases were ineffective(7%),and the total effective rate was 93.33%.In the control group,2 cases were cured(7%),8 cases were effective(27%),16 cases were effective(53%),4 cases were ineffective(13%),and the total effective rate was 86.67%.The comprehensive effect of the treatment group was significantly better than that of the control group(P<0.05).8.Safety:in the course of this study,no obvious adverse reactions and side effects were found in all patients.Conclusion:The clinical effect of new gengaian prescriptions in the treatment of postmenopausal syndrome with Yin deficiency and fire hyperactivity is significant,and it is safe and non-toxic.It can not only significantly improve the clinical symptoms of patients,but also significantly reduce the level of FSH and LH,improve the level of E2 and AMH,and regulate the hormone balance between the pituitary and ovarian axis of menopausal patients.New gengaian prescriptions can also reduce the level of serum IL-6,improve the level of T cell subsets,and improve the immune function of menopausal patients. |
PDF Full Text Request